NCT06885476View on ClinicalTrials.gov

Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients

NARecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 22, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Acute Myeloid LeukemiaMinimal Residual DiseaseNatural Killer Cell
Interventions
BIOLOGICAL

Infusion of alloreactive NK cells

Infusion of alloreactive NK cells for acute leukemia patients harboring minimal residual disease after conventional chemotherapy and prior to allogeneic stem cell transplantation

Trial Locations (1)

40138

RECRUITING

Antonio Curti, Bologna

All Listed Sponsors
lead

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER